CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Achieving stringent complete remission in relapsed/refractory multiple myeloma with liver extramedullary disease after CAR‑T cell therapy: A case report.
Achieving stringent complete remission in relapsed/refractory multiple myeloma with liver extramedullary disease after CAR‑T cell therapy: A case report.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
多发性骨髓瘤(MM)是克隆性浆细胞恶性肿瘤,特征为骨髓浸润及血液和尿液中存在单克隆蛋白。尽管治疗不断进步,复发/难治性MM(RRMM)仍是重大挑战。嵌合抗原受体(CAR)T细胞疗法通过基因工程使T细胞表达可识别肿瘤细胞特定抗原的CAR,已成为RRMM一种有前景的治疗方法。本文报告一例伴肝脏髓外病变(EMD)的RRMM患者,经CAR-T 细胞治疗后达到严格完全缓解。本病例展示了CAR-T 治疗RRMM的疗效,并介绍患者的临床过程、治疗结局和不良反应,同时综述CAR-T 治疗髓外病变的相关文献。
Multiple myeloma (MM) is a clonal plasma cell malignancy characterized by bone marrow infiltration and the presence of monoclonal proteins in the blood and urine.
However, despite the advances that have been made in terms of its treatment, relapsed/refractory MM (RRMM) remains a significant challenge. Chimeric antigen receptor (CAR)-T cell therapy, which involves the engineering of T-cells to express CARs targeting specific antigens on tumor cells, has emerged as a promising therapeutic approach for RRMM.
The present case report presents a patient with RRMM with liver extramedullary disease (EMD) who achieved stringent complete remission following CAR-T cell therapy. This case report highlights the efficacy of CAR-T cell therapy in treating RRMM, also discussing the patient's clinical course, treatment outcomes and side effects, and moreover, a review of the literature that focuses on the treatment of EMD using CAR-T cell therapy.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。